Becton Dickinson (BDX) is showing mixed indications within the bio-tech market. The company has outperformed the earnings and revenue estimates for Q4 while crossing above the 20-day moving average. Recent fiscal reports show growth amidst global challenges, exceeding Q2 earnings estimates and revising its FY24 view. However, BDX's annual guidance fell short, seeing a decrease in short interest and lowered guidance for 2024. Several asset management firms have repositioned their stakes, with both acquisitions and sales observed. BDX's stock has seen fluctuations, underperforming in comparison to competitors on certain trading days, while outperforming on others. Despite lower-than-expected inward interest on the stock's weakness, BDX has maintained its dividends, showing its financial resilience. Interestingly, BDX attained FDA approval for a revolutionary fingertip blood collection device. However, its stock faced downside due to low COVID-19 test demand. The firm continues to be innovative, partnering with Hamilton to standardize single-cell multiomics experiments using robotics.
Becton Dickinson and BDX News Analytics from Wed, 04 Oct 2023 07:00:00 GMT to Wed, 22 May 2024 20:57:03 GMT -
Rating 3
- Innovation 5
- Information 8
- Rumor -2
